NCT02222610View on ClinicalTrials.gov

Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 23, 2014

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Radiation Retinopathy
Interventions
DRUG

0.5 mg ranibizumab

PROCEDURE

Targeted Retinal Photocoagulation (TRP)

TRP to areas of retinal ischemia

Trial Locations (4)

75231

Texas Retina Associates, Dallas

77030

Retina Consultants of Houston/The Medical Center, Houston

77384

Retina Consultants of Houston, The Woodlands

77494

Retina Consultants of Houston, Katy

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Greater Houston Retina Research

OTHER